NYSE$NGVT
Ingevity Corporation · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Ingevity reported a 20% decrease in net sales for Q4 2024, primarily due to strategic repositioning in the Performance Chemicals segment, while adjusted EBITDA increased by 91%.
Ingevity's fourth quarter of 2024 saw a significant 20% decrease in net sales, primarily driven by strategic repositioning actions in the Performance Chemicals segment, which involved exiting lower-margin end markets. Despite this, the company reported a substantial 91% increase in adjusted EBITDA, reflecting the benefits of these repositioning efforts and a non-cash inventory charge in the prior year. Net income for the quarter was $16.6 million, with diluted EPS of $0.46.
- Net sales decreased by 20% to $298.8 million in Q4 2024, mainly due to strategic repositioning in the Performance Chemicals segment.
- Adjusted EBITDA surged by 91% to $80.6 million, with the adjusted EBITDA margin reaching 27.0%.
- Net income for the quarter was $16.6 million, with diluted EPS of $0.46, including pre-tax restructuring charges of $23.4 million.
- Operating cash flow was $64.5 million, and free cash flow was $39.6 million, including a $50.0 million termination fee installment.
Headline financials
Revenue & EPS history
Ingevity · Revenue · Quarterly
$299M
Revenue by segment
Ingevity · $446M total across 3 segments · Q3 2023
- Performance Chemicals$256M-24.1%57.4%
- Performance Materials$147M+1.6%33.0%
- Advanced Polymer Tech$42.8M—9.6%
Forward guidance
Ingevity announced its full year 2025 guidance, projecting sales between $1.3 billion and $1.4 billion, adjusted EBITDA between $400 million and $415 million, and free cash flow between $220 million and $260 million. This guidance excludes potential impacts from exploring strategic alternatives for the Performance Chemicals Industrial Specialties product line and North Charleston CTO refinery.
Tailwinds
- Expected sales between $1.3 billion and $1.4 billion for full year 2025.
- Anticipated adjusted EBITDA between $400 million and $415 million.
- Projected free cash flow between $220 million and $260 million.
- Commitment to enhancing shareholder value through improved EBITDA with margins approaching 30%.
- Expectation to reduce net leverage ratio to below 2.8 times by Q4 2025.
Headwinds
- Guidance does not include potential impact from the exploration of strategic alternatives for the Industrial Specialties product line.
- Guidance does not include potential impact from the exploration of strategic alternatives for the North Charleston CTO refinery.
- The company does not forecast net income for 2025 due to inherent uncertainties in various components.
- Future restructuring and other income (charges) could significantly impact financial measures.
- Additional acquisition and other-related costs, litigation verdict charges, and discrete tax items could drive variability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
+1.9%
Avg return
Earnings day
+1.9%
Avg return
5 days after
+2.2%
Avg return
30 days after
58%
26 / 45 earnings
Positive
+22.0%
Q1 2020
Best reaction
-15.8%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.9% | -8.2% | -15.3% | |
| Q4 2025 | +0.3% | +1.5% | +1.4% | |
| Q3 2025 | -15.8% | -9.1% | -2.8% | |
| Q1 2025 | +0.9% | +9.8% | +7.3% | |
| Q4 2024 | +5.3% | +0.6% | -7.5% | |
| Q3 2024 | +16.5% | +17.5% | +33.5% | |
| Q2 2024 | -7.5% | -23.2% | -14.3% | |
| Q1 2024 | +7.2% | +5.3% | -4.5% | |
| Q4 2023 | +3.1% | +4.7% | +3.1% | |
| Q3 2023 | +5.0% | -0.5% | +1.1% | |
| Q2 2023 | -11.2% | -14.0% | -12.4% | |
| Q1 2023 | -8.4% | -15.9% | -26.3% | |
| Q4 2022 | -6.8% | -7.8% | -21.1% | |
| Q3 2022 | +3.6% | +8.2% | +14.1% | |
| Q2 2022 | +5.0% | +3.0% | +4.2% | |
| Q1 2022 | +9.6% | +9.2% | +19.7% | |
| Q4 2021 | +0.9% | +4.2% | -0.5% | |
| Q3 2021 | -0.6% | -0.5% | -5.6% | |
| Q2 2021 | +5.4% | +1.4% | -1.0% | |
| Q1 2021 | +4.6% | +10.2% | +10.4% | |
| Q4 2020 | -6.6% | -4.6% | +6.3% | |
| Q3 2020 | -1.4% | +0.1% | +8.9% | |
| Q2 2020 | -2.1% | +1.9% | +1.3% | |
| Q1 2020 | +22.0% | +12.2% | +23.8% | |
| Q4 2019 | -2.9% | +2.5% | -24.5% | |
| Q3 2019 | +1.7% | +2.8% | +4.6% | |
| Q2 2019 | -1.2% | -2.9% | -26.9% | |
| Q1 2019 | -10.9% | -9.8% | -23.7% | |
| Q4 2018 | +9.8% | +13.2% | +3.0% | |
| Q3 2018 | +2.3% | -0.6% | +9.8% | |
| Q2 2018 | +11.3% | +10.0% | +14.5% | |
| Q1 2018 | +2.4% | +2.7% | -0.2% | |
| Q4 2017 | +7.3% | +12.3% | +3.8% | |
| Q3 2017 | +2.2% | +5.8% | +11.0% | |
| Q2 2017 | -0.7% | +1.3% | +8.1% | |
| Q1 2017 | -6.5% | -7.2% | -5.4% | |
| Q4 2014 | +4.3% | +2.5% | +6.7% | |
| Q4 2016 | -4.6% | -6.8% | +7.0% | |
| Q3 2015 | +11.0% | +10.8% | +22.7% | |
| Q3 2016 | +7.2% | +8.3% | +21.1% | |
| Q2 2015 | +14.3% | +14.8% | +17.2% | |
| Q2 2016 | +15.8% | +15.8% | +18.4% | |
| Q1 2016 | -0.3% | — | — | |
| Q1 2015 | -0.3% | — | — | |
| Q4 2015 | -0.3% | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro